{"id":"146fba22-9564-57cf-8944-593686b84a4b","stable_key":"8182578e-8d21-598e-a3cb-e62d480d2251:myricetin-sulfate-albumin","predicate":"binds","statement":"The sulfate bound human serum albumin with high affinity and moderately displaced the Site I marker warfarin in vitro.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c361e6da-7634-578c-aa4a-e4389688c06f","mechanism_event_label":"Carrier binding changes the freely available fraction.","subject":{"id":"b71fca58-3e61-5eed-bfa5-4465fcc9407e","slug":"myricetin-3-prime-o-sulfate","display_name":"Myricetin 3′-O-sulfate","entity_type_key":"small_molecule"},"object":{"id":"d74adc7c-c253-5604-99bf-73d5ed0c0701","slug":"human-serum-albumin","display_name":"Human serum albumin","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"c361e6da-7634-578c-aa4a-e4389688c06f","stable_key":"8182578e-8d21-598e-a3cb-e62d480d2251:myricetin-sulfate-albumin-event","event_type":"observed_relationship","label":"Carrier binding changes the freely available fraction.","description":"The sulfate bound human serum albumin with high affinity and moderately displaced the Site I marker warfarin in vitro.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"b71fca58-3e61-5eed-bfa5-4465fcc9407e","slug":"myricetin-3-prime-o-sulfate","display_name":"Myricetin 3′-O-sulfate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d74adc7c-c253-5604-99bf-73d5ed0c0701","slug":"human-serum-albumin","display_name":"Human serum albumin","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"fafe05e7-4874-56e6-a42a-2ebf1ab2dd57","slug":"myricetin","display_name":"Myricetin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"ee94b256-deeb-5795-8b6e-6e388576d464","slug":"warfarin","display_name":"Warfarin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Albumin fluorescence and ultrafiltration assays.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not demonstrated displacement toxicity or a change in patient anticoagulation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"myricetin","display_name":"Myricetin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Carrier binding changes the freely available fraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"bf1dd0cb-f2ff-5d44-9751-92f32ace3ef3","evidence_kind":"source_excerpt","locator":"Lines 172-178","start_line":172,"end_line":178,"excerpt":"## myricetin-sulfate-albumin\nCarrier binding changes the freely available fraction.\nThe sulfate bound human serum albumin with high affinity and moderately displaced the Site I marker warfarin in vitro.\nModel: Albumin fluorescence and ultrafiltration assays.\nLimitations: Not demonstrated displacement toxicity or a change in patient anticoagulation.\nEvidence access: Primary full text\nInteraction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021","model_system":"Albumin fluorescence and ultrafiltration assays.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"58045cd9-3b27-5469-bb4b-e1c6a9bdca34","stable_key":"import-8182578e-8d21-598e-a3cb-e62d480d2251","title":"Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"0abf512275cf3aae9e4ec8544f1cde97e0155d0cfb5be12a193cdd5a898386a7","revision_id":"422e342f-a55c-5e73-ba98-43df560f49b9","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}